Castle Creek Pharmaceuticals Announces First IGA Scale for Epidermolysis Bullosa Simplex Clinical Research
Company also presents findings from proof-of-concept study of diacerein 1% ointment at 47th Annual ESDR Meeting 2017
Sep 27, 2017, 08:30 ET
PARSIPPANY, N.J., Sept. 27, 2017 /PRNewswire/ -- Castle Creek Pharmaceuticals (CCP), a global company dedicated to delivering transformative therapies to patients with orphan dermatologic and other underserved conditions, today announced the development and validation of the first Investigator's Global Assessment (IGA) scale to be used by clinicians evaluating the average overall severity of epidermolysis bullosa simplex (EBS) lesions in clinical trials. The new IGA scale is being presented at the 47th Annual ESDR Meeting 2017 held at the Salzburg Congress Centre in Salzburg, Austria September 27-30th, 2017.
The five-point IGA scale for overall clinical assessment defines EBS-involved skin as Clear, Almost Clear, Mild, Moderate, and Severe, based on the presence or absence of blisters and factors including blister size, erosions, crusting and erythema. The IGA scale will be used to evaluate the safety and efficacy of diacerein 1% ointment, an investigational topical being developed by CCP for the treatment of EBS, in the ongoing Phase 2/3 DELIVERS study.
Alain Hovnanian, MD, PhD, department of genetics at the University Paris Descartes in Paris, France, will present the IGA scale during a special poster walk session, "Clinical Outcomes 3: Bullous diseases and other entities," on Saturday, September 30th, from 10:30-11:30am CEST.
"We have standard instruments in place for evaluating therapies for epidermolysis bullosa in general, but until now no such instrument has been validated for evaluating the severity of EBS lesions specifically," said Dr. Hovnanian. "This first-of-its-kind IGA scale will serve an important role in advancing clinical research and determining the efficacy of potential therapies for the most common form of epidermolysis bullosa."
In a separate presentation that has also been selected for the "Clinical Outcomes 3: Bullous diseases and other entities" poster walk session, Michael Ablinger, MSc, scientific associate at the EB House Austria, will discuss results from a proof-of-concept study evaluating the safety of diacerein 1% ointment topically applied in generalized-severe EBS.
In the study, researchers analyzed the metabolization of diacerein 1 % ointment both in vitro and in vivo. A Franz diffusion cell setup demonstrated complete conversion into rhein within the skin, and bio-transformation into rhein was also observed in patients upon topical application. Treatment of 3% of the body surface for four weeks resulted in systemic rhein levels that were approximately 150-fold lower than levels detected 24 hours after single-dose oral intake.
"Our results demonstrate that the prodrug diacerein is converted into its active form rhein within the skin," said Ablinger. "The process allows for an anti-inflammatory effect in the skin of EBS patients."
For more information about the 47th Annual ESDR Meeting 2017, visit http://www.esdr2017.org.
About Castle Creek Pharmaceuticals
Castle Creek Pharmaceuticals (CCP) is a privately held biopharmaceutical company with a robust and diversified pipeline of late-stage products. The company business strategy is based on a demonstrated ability to identify and advance therapies backed by strong science with the potential to represent significant advances in the treatment of debilitating dermatologic and head and neck conditions with high unmet needs. CCP is working with TWi Biotechnology, Inc. based in Taipei, Taiwan for manufacture and development of CCP-020. For more information, please visit www.castlecreekpharma.com.
Media contact:
Adam Daley
Berry & Company Public Relations
212-253-8881
[email protected]
SOURCE Castle Creek Pharmaceuticals
Share this article